Key result
HFAM model links torsadogenic hERG blockers to increased sympathetic-parasympathetic co-activation.
Why the study?
Does the high-frequency autonomic modulation (HFAM) model accurately differentiate specific states of cardiac autonomic control, including sympathetic-parasympathetic co-activation, across humans and preclinical animal models?
Observational (n=327)
Open-label
Yes
Does the high-frequency autonomic modulation (HFAM) model accurately differentiate specific states of cardiac autonomic control, including sympathetic-parasympathetic co-activation, across humans and preclinical animal models?
The HFAM model provides a novel translational method to detect simultaneous sympathetic and parasympathetic co-activation from 10-second ECG intervals, offering improved sensitivity over traditional spectral HRV analysis for evaluating pro-arrhythmic drug risk and autonomic imbalance.
Answers are grounded in this paper and cite their sources.
May support torsadogenic risk assessment via autonomic monitoring; leaves open clinical adoption pending prospective validation.
BACKGROUND AND PURPOSE: Increase in high-frequency beat-to-beat heart rate oscillations by torsadogenic hERG blockers appears to be associated with signs of parasympathetic and sympathetic co-activation which cannot be assessed directly using classic methods of heart rate variability analysis. The present work aimed to find a translational model that would allow this particular state of the autonomic control of heart rate to be assessed. EXPERIMENTAL APPROACH: High-frequency heart rate and heart period oscillations were analysed within discrete 10 s intervals in a cohort of 200 healthy human subjects. Results were compared to data collected in non-human primates and beagle dogs during pharmacological challenges and torsadogenic hERG blockers exposure, in 127 genotyped LQT1 patients on/off β-blocker treatment and in subgroups of smoking and non-smoking subjects. KEY RESULTS: Three states of autonomic modulation, S1 (parasympathetic predominance) to S3 (reciprocal parasympathetic withdrawal/sympathetic activation), were differentiated to build a new model of heart rate variability referred to as high-frequency autonomic modulation. The S2 state corresponded to a specific state during which both parasympathetic and sympathetic systems were coexisting or co-activated. S2 oscillations were proportionally increased by torsadogenic hERG-blocking drugs, whereas smoking caused an increase in S3 oscillations. CONCLUSIONS AND IMPLICATIONS: The combined analysis of the magnitude of high-frequency heart rate and high-frequency heart period oscillations allows a refined assessment of heart rate autonomic modulation applicable to long-term ECG recordings and offers new approaches to assessment of the risk of sudden death both in terms of underlying mechanisms and sensitivity.
No takes yet. Share an insight, caveat, or question.
Champéroux et al. (2018) conducted an observational in Autonomic cardiac modulation and Long QT Syndrome Type 1 (LQT1) (n=327). High-frequency autonomic modulation (HFAM) model under pharmacological challenges (beta-blockers, atenolol, clonidine, atropine, torsadogenic hERG blockers) and smoking vs. Baseline/vehicle, non-smoking, or off beta-blocker treatment was evaluated on Proportions of high-frequency autonomic modulation states (S1, S2, S3) and HFAM ratio (HFHRN/HFRRN) within discrete 10-second ECG intervals (p=≤0.05). The high-frequency autonomic modulation (HFAM) model differentiated three autonomic states, showing S2 (sympathetic-parasympathetic co-activation) increased with torsadogenic hERG blockers.
Synapse has enriched 10 related papers. Consider them for comparative context: